Last reviewed · How we verify

NCT03827005

L-arginine Supplementation and Resistance Exercise

Completed NA Last updated 1 February 2019
What this trial tests

NA trial testing L-arginine in Healthy Adult in 30 participants. Completed in 30 May 2017.

Timeline
16 July 2016
Primary endpoint
30 April 2017
30 May 2017

Quick facts

Lead sponsorNorth Dakota State University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeother
Enrollment30
Start date16 July 2016
Primary completion30 April 2017
Estimated completion30 May 2017

Drugs / interventions tested

Conditions studied

Sponsor

North Dakota State University

Who can join

Adults 18 to 25, any sex, with Healthy Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to examine the acute endothelial, cardiovascular, and performance responses to L-arginine by assessing flow-mediated dilation (FMD) and heart rate variability (HRV) both before and after resistance exercise to fatigue. Thirty (15 male, 15 female) physically active participants volunteered for a randomized, cross-over, double-blind, placebo- controlled clinical trial. Participants completed five sets of elbow extension-flexion exercise after consumption of either 3 g of placebo or 3 g L-arginine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of L-arginine

Trials testing the same drug.

Other recruiting trials for Healthy Adult

Currently open trials in the same condition.

Other North Dakota State University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03827005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing